ATI RN
ATI Pharmacology Proctored Exam 2019
1. When administering subcutaneous enoxaparin 40 mg using a prefilled syringe of Enoxaparin 40 mg/0.4 mL to an adult client following hip arthroplasty, what action should the nurse plan to take?
- A. Expel any air bubbles from the prefilled syringe before injecting.
- B. Insert the needle completely into the client's tissue.
- C. Administer the injection in the client's thigh.
- D. Aspirate carefully after inserting the needle into the client's skin.
Correct answer: B
Rationale: When administering enoxaparin via a prefilled syringe for deep subcutaneous injection, the nurse should insert the needle completely into the client's tissue. This action ensures proper delivery of the medication into the subcutaneous layer, promoting optimal therapeutic effects. Choice A is incorrect because there is no need to expel air bubbles from a prefilled syringe. Choice C is incorrect as enoxaparin is typically administered in the abdomen for subcutaneous injections. Choice D is incorrect as aspiration is not recommended for subcutaneous injections to avoid trauma or damage to tissues.
2. A healthcare professional is educating a client who is beginning therapy with gemcitabine. Which of the following findings should the healthcare professional instruct the client to report?
- A. Dyspnea
- B. Constipation
- C. Tinnitus
- D. Dry mouth
Correct answer: A
Rationale: The correct answer is dyspnea. Dyspnea can indicate pulmonary toxicity, a severe adverse effect associated with gemcitabine therapy. Prompt reporting of dyspnea allows for timely evaluation and management to prevent potential complications. Constipation, tinnitus, and dry mouth are not typically associated with gemcitabine therapy and are less likely to be directly related to the medication. Therefore, they are not the priority findings that the client should report.
3. A client with increased intracranial pressure is receiving Mannitol. Which finding should the nurse report to the provider?
- A. Blood glucose 150 mg/dL
- B. Urine output 40 mL/hr
- C. Dyspnea
- D. Bilateral equal pupil size
Correct answer: C
Rationale: Dyspnea is a concerning finding in a client receiving Mannitol as it can be a manifestation of heart failure, an adverse effect of the medication. It suggests potential fluid overload or exacerbation of heart conditions, both of which require immediate attention. Reporting dyspnea promptly allows for timely evaluation and management. Blood glucose levels and urine output are important parameters to monitor but are not directly related to the administration of Mannitol for increased intracranial pressure. Bilateral equal pupil size is a normal and expected finding.
4. What is a desired outcome of the drug Phenytoin?
- A. Decrease symptoms of PTSD
- B. Resolution of signs of infection
- C. Decrease or cessation of seizures without excessive sedation
- D. Prevention or relief of bronchospasm
Correct answer: C
Rationale: The correct answer is C: Decrease or cessation of seizures without excessive sedation. Phenytoin is primarily used as an antiepileptic medication to manage and prevent seizures. It does not directly impact symptoms of PTSD (Choice A), resolution of signs of infection (Choice B), or prevention or relief of bronchospasm (Choice D). Therefore, the desired outcome of Phenytoin is to control seizures effectively while avoiding excessive sedation.
5. Which of the following conditions are not treated with Barbiturates?
- A. Seizures
- B. Hypotension
- C. Insomnia
- D. Anxiety
Correct answer: B
Rationale: Hypotension is not treated with barbiturates. Barbiturates are primarily used for treating seizures, insomnia, and anxiety, but they are not indicated for the treatment of hypotension.
Similar Questions
Access More Features
ATI RN Basic
$69.99/ 30 days
- 5,000 Questions with answers
- All ATI courses Coverage
- 30 days access
ATI RN Premium
$149.99/ 90 days
- 5,000 Questions with answers
- All ATI courses Coverage
- 30 days access